Table 1. Demographic and Clinical Characteristics of the Two Cohorts of Patients.

Variable	Gene-Expression Profiling (N = 130)			Immunohistochemical Analysis (N = 166)
	Treatment Success (N = 92)	Treatment Failure (N = 38)	P Value	Treatment Success (N = 87)	Treatment Failure (N = 79)	P Value
Median age (range) — yr	37 (8–80)	46 (12–84)	0.03	33 (16–80)	36 (15–82)	0.21
Male sex — %	51	68	0.08	51	53	0.74
Histologic subtype — %			0.15			0.19
Nodular sclerosis	82	63		89	80
Mixed cellularity	12	26		6	8
Lymphocyte-rich	2	3		0	4
Lymphocyte-depleted	1	5		0	3
Not classifiable	3	3		6	6
Stage — %			0.003			0.01
I	14	8		11	3
II	60	32		53	39
III	16	37		20	34
IV	10	24		16	24
Presence of constitutional symptoms — %	36	50	0.14	40	53	0.10
Tumor size			0.39			0.27
Median (range) — cm†	6 (2–17)	7 (2–26)		6 (0–28)	7 (0–19)
≥10 cm — %	18	26		33	30
IPS ≥4 (high risk) — %‡	14	18	0.05	14	20	0.27
Primary treatment — %			1.00			0.32
ABVD chemotherapy with or without radiation	96	95		99	100
Extended-field radiation alone	4	5		1	0
Secondary treatment — %
Autologous stem-cell transplantation	ND	ND		NA	70
Other therapy with curative intent (CVPP or GDP plus radiation)	ND	ND		NA	8
Palliative treatment (including single-agent chemotherapy or radiation)	ND	ND		NA	22

^*ABVD denotes doxorubicin, bleomycin, vinblastine, and dacarbazine, CVPP cyclophosphamide, vinblastine, procarbazine, and prednisone, GDP gemcitabine, dexamethasone, and cisplatin, IPS International Prognostic Score, NA not applicable, and ND not done.

^†The tumor size was calculated as the longest diameter of the largest involved area.

^‡The IPS ranges from 0 to 7, with higher scores indicating increased risk.